EdgarLookup

Aquestive Therapeutics, Inc. — All Filings

618 total filings on record

Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.

Overview All Filings Financials Insiders
All 10-K 10-Q 144 3 3/A 4 4/A 424B2 424B3 424B4 424B5 8-A12B 8-K ARS CERT CORRESP CT ORDER D DEF 14A DEFA14A DRS DRS/A DRSLTR EFFECT PRE 14A RW S-1 S-1/A S-1MEF S-3 S-8 SC 13G SC 13G/A SCHEDULE 13G SCHEDULE 13G/A UPLOAD
Form Description Accession Number Filed Period
8-K 8-K 0001398733-26-000020 Mar 20, 2026 Mar 16, 2026
4 PRIMARY DOCUMENT 0001214659-26-003147 Mar 11, 2026 Mar 9, 2026
4 PRIMARY DOCUMENT 0001214659-26-003146 Mar 11, 2026 Mar 9, 2026
4 PRIMARY DOCUMENT 0001214659-26-003145 Mar 11, 2026 Mar 9, 2026
4 PRIMARY DOCUMENT 0001214659-26-003144 Mar 11, 2026 Mar 9, 2026
4 PRIMARY DOCUMENT 0001214659-26-003143 Mar 11, 2026 Mar 9, 2026
4 PRIMARY DOCUMENT 0001214659-26-003142 Mar 11, 2026 Mar 9, 2026
4 PRIMARY DOCUMENT 0001214659-26-003141 Mar 11, 2026 Mar 9, 2026
4 PRIMARY DOCUMENT 0001214659-26-003140 Mar 11, 2026 Mar 9, 2026
4 PRIMARY DOCUMENT 0001214659-26-003134 Mar 11, 2026 Mar 9, 2026
3 PRIMARY DOCUMENT 0001214659-26-003133 Mar 11, 2026 Mar 2, 2026
S-8 0001214659-26-002827 Mar 4, 2026
10-K 10-K 0001398733-26-000018 Mar 4, 2026 Dec 31, 2025
8-K 8-K 0001398733-26-000016 Mar 4, 2026 Mar 3, 2026
8-K 8-K 0001398733-26-000007 Feb 26, 2026
8-K 8-K 0001398733-26-000005 Feb 2, 2026 Jan 30, 2026
S-8 0001214659-26-000711 Jan 21, 2026
8-K 8-K 0001398733-26-000003 Jan 9, 2026
4 PRIMARY DOCUMENT 0001214659-25-017652 Dec 5, 2025 Dec 4, 2025
4 PRIMARY DOCUMENT 0001214659-25-017591 Dec 4, 2025 Dec 2, 2025
144 0001968582-25-001073 Nov 17, 2025
SCHEDULE 13G 0001493215-25-000037 Nov 14, 2025
4 PRIMARY DOCUMENT 0001214659-25-016275 Nov 12, 2025 Nov 10, 2025
3 PRIMARY DOCUMENT 0001214659-25-016274 Nov 12, 2025 Nov 3, 2025
8-K 8-K 0001398733-25-000030 Nov 6, 2025
10-Q 10-Q 0001398733-25-000028 Nov 5, 2025 Sep 30, 2025
8-K 8-K 0001398733-25-000027 Nov 5, 2025
4 PRIMARY DOCUMENT 0001214659-25-015048 Oct 17, 2025 Oct 15, 2025
4 PRIMARY DOCUMENT 0001214659-25-015047 Oct 17, 2025 Oct 15, 2025
4 PRIMARY DOCUMENT 0001214659-25-015046 Oct 17, 2025 Oct 15, 2025
SCHEDULE 13G/A 0002012383-25-002498 Oct 17, 2025
144 0001968582-25-000998 Oct 15, 2025
144 0001950047-25-007999 Oct 15, 2025
144 0001628280-25-045063 Oct 15, 2025
8-K 8-K 0001398733-25-000022 Oct 8, 2025
8-K 8-K 0001398733-25-000020 Oct 1, 2025
4 PRIMARY DOCUMENT 0001214659-25-014288 Sep 29, 2025 Sep 26, 2025
4 PRIMARY DOCUMENT 0001214659-25-014287 Sep 29, 2025 Sep 26, 2025
144 0001628280-25-043082 Sep 29, 2025
144 0001950047-25-007535 Sep 26, 2025
4 PRIMARY DOCUMENT 0001214659-25-014009 Sep 22, 2025 Sep 19, 2025
144 0001950047-25-007378 Sep 19, 2025
4 PRIMARY DOCUMENT 0001214659-25-013493 Sep 8, 2025 Sep 4, 2025
4 PRIMARY DOCUMENT 0001214659-25-013485 Sep 8, 2025 Sep 5, 2025
8-K 8-K 0001398733-25-000018 Sep 8, 2025
144 0002007317-25-001032 Sep 5, 2025
144 0001950047-25-006754 Sep 4, 2025
8-K 8-K 0001398733-25-000016 Sep 4, 2025
4 PRIMARY DOCUMENT 0001214659-25-012304 Aug 15, 2025 Aug 14, 2025
8-K 8-K 0001140361-25-031374 Aug 15, 2025 Aug 14, 2025